Scarica l'app Stockscreener
1.25
0.00%
0.00
Dopo l'orario di chiusura:
1.25
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TPST Giù?
Forum
Previsione
Frazionamento azionario
Tempest Therapeutics Inc Borsa (TPST) Ultime notizie
Tempest Therapeutics (TPST) Edges Higher as Stock Tests Resistance Near $1.34EMA Signal - newsline.com
Director Richey William Drake reports 2,000 TPST shares on Form 3 - Stock Titan
Tempest Therapeutics (TPST) director awarded 25,000 stock options at $1.27 strike - Stock Titan
Warrant share approvals on ballot at Tempest Therapeutics (NASDAQ: TPST) - Stock Titan
Tempest Therapeutics Announces CFO Transition and Board Changes - TipRanks
Tempest Therapeutics appoints two directors to board - Investing.com UK
Tempest Therapeutics appoints two directors to board By Investing.com - Investing.com South Africa
Tempest Therapeutics (NASDAQ: TPST) CFO to depart while two independent directors join board - Stock Titan
Tempest Therapeutics, Inc. Announces Executive Changes, Effective June 5, 2026 - marketscreener.com
Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors - GlobeNewswire
Tempest Therapeutics Executes Warrant-Inducement Equity Financing Deal - The Globe and Mail
Tempest Therapeutics Raises $2.0M via Warrant Exercise, Issues New and Placement Agent Warrants - TradingView
Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds - 富途牛牛
TEMPEST THERAPEUTICS INC WT EXP Company Profile & Introduction - Moomoo
Tempest Therapeutics (TPST) inks $2M warrant exercise and new warrant deal - Stock Titan
Tempest Therapeutics, Inc. Files 8-K SEC Report Detailing Company Information and Stock Listing on NASDAQ - Minichart
Tempest Therapeutics Announces Resignation of Board Director - TipRanks
Tempest Therapeutics (TPST) asks shareholders to approve warrants convertible into millions of shares - Stock Titan
Tempest Therapeutics (TPST) director Simantov resigns and waives unpaid fees - Stock Titan
TPST Q1 2026 Earnings: Significant EPS Miss and No Revenue Reflect Pre-Revenue Stage PressuresNegative Surprise Momentum - The Legal Advocate
Tempest Therapeutics Q1 2026 Earnings: Wider-than-Expected Loss Amid Pre-Revenue Development StageEPS Surprise History - The Legal Advocate
Tempest Therapeutics secures $2M from warrant exercise By Investing.com - Investing.com Nigeria
Tempest Therapeutics secures $2M from warrant exercise - Investing.com
Tempest Therapeutics Announces Agreement for Warrant Exercise and New Short-Term Warrants - Quiver Quantitative
Tempest Therapeutics (TPST) Slumps 10%: Support Levels Under ScrutinyNegative Gamma - newsline.com
Tempest Therapeutics Inc. (TPST) Q1 2026 Earnings: Significant EPS Miss with No Revenue; Stock Edges UpInterim Report - Newser
Tempest Therapeutics announces resignation of three board members By Investing.com - Investing.com India
Tempest Therapeutics stock falls after $4.25 million direct offering - MSN
Tempest Therapeutics, Inc. Files Form 8-K with SEC – Company Information and Security Details (May 22, 2026) - Minichart
Tempest Therapeutics, Inc. 8-K Filing Details and Entity Information for May 19, 2026 - Minichart
Tempest Therapeutics (TPST) Edges Higher as Biotech Sector Shows Renewed InterestDiamond Pattern - Newser
Tempest Therapeutics announces resignation of three board members - Investing.com
Tempest Therapeutics Faces Nasdaq Listing and Governance Risks - TipRanks
Tempest Therapeutics Announces Multiple Board Director Resignations - TipRanks
Tempest Therapeutics receives Nasdaq notice for listing deficiencies - Investing.com UK
Tempest Therapeutics receives Nasdaq notice for listing deficiencies By Investing.com - Investing.com South Africa
Nasdaq flags Tempest Therapeutics (NASDAQ: TPST) on equity and board gaps - Stock Titan
[8-K] Tempest Therapeutics, Inc. Reports Material Event - Stock Titan
TPST Q1 2026 Earnings: Deep EPS Miss Highlights Clinical-Stage Biotech ChallengesNext Quarter Guidance - The Legal Advocate
TPST Q1 2026 Earnings: Deep EPS Miss Highlights Clinical-Stage ChallengesEPS Growth Rate - The Legal Advocate
Tempest Therapeutics (TPST) Stock: Jumps +3.65%, Approaching $1.93 2026-05-20Percent Below MA - Newser
Press Releases about Tempest Therapeutics, Inc.Common Stock - The Chronicle-Journal
Tempest Therapeutics | 10-Q: Q1 2026 Earnings Report - Moomoo
Tempest Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Tempest Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Tempest Therapeutics (NASDAQ: TPST) Q1 2026 loss widens on CAR-T deal charges and low cash - Stock Titan
Tempest Therapeutics reports Q1 2026 net loss of $27.7M, cash $1.8M - TradingView
Tempest Therapeutics Q1 net loss widens on asset acquisition costs - TradingView
Tempest Therapeutics (TPST) posts $27.7M loss, highlights 100% CAR‑T responses - Stock Titan
Tempest CAR-T trials log 100% response in 15 patients - Stock Titan
Tempest Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewswire
MSN Money - MSN
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):